Mexico adds a public-sector EMAT registration gate, Brazil opens an IVD implementation window, and Ecuador consults on device-registration notifications.
Mexico · Brazil · Ecuador
Mexico has added a new registration gate for high-technology medical equipment sold into public institutions, Brazil has opened a defined SUS access window for a molecular diagnostic, and Ecuador has started a device-specific consultation on post-registration notifications.
The common thread is operational: manufacturers and registration holders now have concrete deadlines to manage before public procurement, technology incorporation, or post-registration changes can proceed smoothly.
Mexico’s Ministry of Health published new Plan Maestro Nacional registration-folio guidelines on August 10. They took effect on August 11.
The guidelines require public Sistema Nacional de Salud projects involving the creation, substitution, or expansion of medical units, as well as acquisitions of high-technology medical equipment, to obtain a Folio de Registro through the Plan Maestro Nacional. The requirement applies regardless of the project’s funding source.
High-technology medical equipment, or EMAT, is defined as medical equipment used for advanced diagnostic or treatment functions that involves technological complexity, specialized handling, and high cost. Existing projects and equipment acquisitions that remain unregistered must request regularization within 60 calendar days after the rules became effective.
Why it matters: This is not a COFEPRIS product-registration change. It is a buyer-side public-infrastructure and procurement gate. Manufacturers and distributors should confirm that a public-institution customer has the required folio before treating a capital-equipment opportunity as procurement-ready.
Action: Review active Mexican public-sector opportunities now. Identify which buyers need regularization, assign ownership for the folio check, and incorporate the new dependency into commercial forecasts and tender planning.
Brazil’s Ministry of Health published Portaria SCTIE/MS No. 51/2026 on August 4. The measure incorporates qualitative real-time PCR detection of Mycobacterium leprae into SUS as an aid to leprosy diagnosis using intradermal scraping, skin biopsy, or nerve-biopsy specimens.
The responsible technical areas have up to 180 days to make the offering available within SUS.
Market-access implication: IVD manufacturers with an applicable molecular assay should treat incorporation as the start of an implementation and supply-readiness period, not as an automatic purchase order. ANVISA registration, technical fit, procurement eligibility, supply capacity, and tender monitoring must be aligned during the 180-day window.
Brazil also published ANVISA RE No. 3.078/2026 on August 10, approving specified transfers of medical-device registration ownership. The resolution reiterates the 30-day instructions-for-use repository-upload obligation and delays its own entry into force for 90 days.
Operational implication: Transferees should not assume immediate reliance on the transferred registrations. The 90-day deferral and the 30-day document-upload requirement need to be reflected in transaction closing, inventory, labeling, and commercialization plans.
ARCSA opened a public consultation on August 4 for a new external instructive covering notifications to sanitary registrations for human-use medical devices. Comments are due September 1, 2026.
The consultation concerns the mechanics for notifying changes associated with an existing device registration. Registration holders and local representatives should compare the draft against their current change-control procedures and identify any notification trigger, document requirement, or implementation burden that needs clarification before the text is finalized.
Ecuador also has active consultations touching medical-device storage, distribution, and transport practices, as well as establishment operating permits. This makes August an unusually active policy window for companies maintaining Ecuadorian registrations or local distribution infrastructure.
Action: Submit targeted comments rather than general objections. Focus on ambiguous notification categories, evidence requirements, transition treatment, and consistency with existing registration-holder obligations.
This week’s developments operate at three different points in the market-access lifecycle: Mexico adds a public-purchasing gate, Brazil creates an implementation window after health-technology incorporation and clarifies timing around ownership transfers, and Ecuador invites input on post-registration change notifications.
For device and IVD sponsors, the practical lesson is to manage market access beyond the initial sanitary registration. Procurement readiness, ownership-transfer timing, repository obligations, and post-registration change control can determine when a registered product can actually be purchased, supplied, or modified.
bioaccess® helps medical-technology companies map these country-specific dependencies and build registration and commercialization plans that preserve sponsor control. Contact our team when a LATAM rollout requires coordinated regulatory, local-representation, and post-registration execution.
← All LATAM Regulatory Dispatch editions · Contact bioaccess®